• SNAI1, EMT, and Stemness in Thymic Tumors

  2026-08-26

  A 2024 study identifies SNAI1 as an oncogenic hub in thymic epithelial tumors and links it to epithelial–mesenchymal transition, cancer stem cell-like traits, macrophage remodeling, and the PIK3R2/p-EphA2 signaling axis. Its integrated genomic, single-cell, chromatin, biochemical, and in vivo approach provides a mechanistic framework for investigating aggressive thymic tumors and evaluating SNAI1-directed strategies.

• Puromycin dihydrochloride: Practical Selection Guide

  2026-08-26

  Puromycin dihydrochloride provides a controllable way to select pac-expressing cells and suppress protein synthesis in translation-focused workflows. It is suitable for cell-line selection and carefully controlled mechanistic assays, but should not be treated as a universal selection dose or standalone proof of autophagy.

• HyperScribe™ Poly (A) Tailing Kit Workflow

  2026-08-25

  Build translation-ready RNA for controlled rescue, transfection, and micro-injection studies with an enzymatic polyadenylation workflow. The HyperScribe™ Poly (A) Tailing Kit adds a practical post-transcriptional optimization step that connects RNA quality control with functional gene-expression assays.

• Cyanine 5-dCTP for Reliable DNA Assays

  2026-08-25

  Learn how Cyanine 5-dCTP (SKU B8161) can strengthen DNA probe synthesis and fluorescence-based nucleic acid detection without being mistaken for a direct cell-viability dye. This scenario-driven guide covers compatibility, storage, data interpretation, and evidence-based vendor selection.

• ML133 HCl: Kir2.1 Inhibition Workflow

  2026-08-24

  ML133 HCl enables selective chemical interrogation of Kir2.1 potassium channel function in pulmonary vascular and cardiovascular models. This workflow translates published PASMC findings into practical controls, dosing logic, assay choices, and troubleshooting steps without confusing channel inhibition with downstream pathway blockade.

• WP1066: Practical JAK2/STAT3 Inhibition Workflows

  2026-08-24

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor for connecting pathway biochemistry with measurable changes in cancer-cell growth, apoptosis, and tumor signaling. This guide provides dose–time assay design, renal carcinoma and AML use-cases, translational interpretation, and troubleshooting informed by a recent macrophage-focused biomaterials study.

• Kanamycin Sulfate in CircRNA Production Workflows

  2026-08-23

  Kanamycin Sulfate is a water-soluble antibiotic useful for controlled bacterial selection upstream of circular RNA production. This article explains how to separate antibiotic selection from circRNA purification, using recent ultrafiltration findings to improve process design and analytical decisions.

• Sex Differences in Angiotensin II Hypertension

  2026-08-22

  Xue, Pamidimukkala, and Hay used telemetry in conscious, freely moving mice to show that angiotensin II produces a substantially greater hypertensive response in males than in females. Their findings connect this divergence to sex-dependent hormone effects, baroreflex resetting, and sympathetic contributions, providing a framework for sex-stratified cardiovascular experiments.

• Small-Molecule Generation of Pancreatic Ductal Organoids

  2026-08-22

  Liao and colleagues describe a small-molecule cocktail that improves the initiation and expansion of pancreatic ductal organoids derived from Sox9-positive ductal cells. The resulting cultures retain heterogeneous ductal and acinar components and support long-term propagation, creating a practical platform for pancreatic disease modeling and potential high-throughput screening.

• PTH (1-34) Across Bone and Kidney Models

  2026-08-21

  Parathyroid hormone (1-34) (human) provides a mechanistically defined way to interrogate receptor-driven calcium biology across bone, renal, and advanced human model systems. This thought-leadership article connects established PTH signaling with spatially patterned kidney assembloids while distinguishing validated evidence from forward-looking translational hypotheses.

• Dacomitinib Beyond EGFR: From Signaling to Cell Death

  2026-08-20

  Dacomitinib (PF-00299804) offers a mechanistically rich platform for studying irreversible pan-HER signaling blockade, apoptosis, cell-cycle control, and emerging mitochondrial ferroptosis biology. This article connects validated ErbB pharmacology with the METTL17–mitochondrial translation axis while clearly separating established evidence from translational hypotheses.

• B. fragilis and Gut–Brain Cholinergic Seizure Control

  2026-08-20

  Jia et al. identify a gut–vagus–brain cholinergic circuit through which Bacteroides fragilis suppresses seizures, linking colonic ChAT-positive cells, vagal transmission, and intestinal Lactobacillus enrichment. The combination of mouse circuit experiments and a randomized pediatric trial provides a mechanistic framework for microbiota-targeted treatment of refractory epilepsy, while leaving important questions about microbial ecology and human translation.

• Kanamycin Sulfate in RNA and Microbiology Workflows

  2026-08-19

  Kanamycin Sulfate provides reliable selective pressure during bacterial plasmid propagation while its water solubility supports practical media preparation. This guide connects antibiotic selection with circRNA production and ultrafiltration, clarifying where the reagent helps, where it does not, and how to troubleshoot each handoff.

• Palbociclib: From G1 Arrest to Assay Insight

  2026-08-19

  Palbociclib and PD0332991 are powerful tools for dissecting CDK4/6-dependent proliferation, but reduced viability does not always mean tumor-cell eradication. This guide connects cell-cycle readouts with the CD109-driven stemness and chemoresistance biology reported in colorectal cancer to improve assay interpretation.

• Gefitinib Resensitizes Cisplatin-Resistant NSCLC

  2026-08-18

  This study identifies abnormal EGFR phosphorylation as a potential off-target mechanism of cisplatin resistance in wild-type EGFR non-small cell lung cancer cells. It further shows that gefitinib can enhance cisplatin-associated growth inhibition and apoptosis in resistant cell models and suppress tumor growth in an H358R xenograft model.

8486 records 1/566 page Next 12345 下5页 Last page